p2

Cambridge Healthtech Institute’s Inaugural

Cell Therapy Analytics and Manufacturing
( 細胞治療薬の分析と製造 )

1月23日~24日

Part of the Cell & Gene Therapies pipeline

Cambridge Healthtech Institute’s Inaugural Cell Therapy Analytics and Manufacturing conference will discuss opportunities, advances and challenges facing the analysis and manufacture of autologous and allogenic cell therapies. The conference will discuss analytical, CMC and quality challenges of cell therapies. The conference will also discuss challenges in manufacturing, scale up, bioreactors, next-generation production technologies, automation, supply chain and other manufacturing related issues. We are seeking cutting edge research findings and unpublished data to be featured at this forum.

Preliminary Agenda

STRATEGIES, REGULATIONS AND GUIDANCE

Regulatory and Commercialization Challenges for Cell Therapy Products

Mo Heidaran, PhD, Vice President, Technical, PAREXEL Consulting, PAREXEL International

Cell Drug Product Manufacturing

Ta-Chun Hang, PhD, Senior Scientist, Process Development, Bluebird bio

Reprogramming Natural Killer Cells for Immunotherapy of Solid Tumors

Sandro Matosevic, PhD, Assistant Professor, Department of Industrial and Physical Pharmacy, Purdue University

ANALYTICAL TOOLBOX AND CMC STRATEGIES

Assay Development and Method Validation for Cell Therapies

Speaker to be Announced

PROCESS DEVELOPMENT SCALE-UP AND MANUFACTURING

Manufacturing and Bioproduction Challenges and Opportunities for Cell Therapies

Vijay Chiruvolu, PhD, Senior Vice President of Global Process Development - Cell Therapy, Kite Pharma, a Gilead Sciences Company

Challenges of Scaling Up Cell-Based Processes to Meet Pivotal Trial Requirements

Kelly Kemp, PhD, Director, Process Development, ViaCyte



* 不測の事態により、事前の予告なしにプログラムが変更される場合があります。

Choose your language
Traditional Chinese
Simplified Chinese
Korean
English


更新通知サービス




2020年のカンファレンスプログラムと研修セミナー


メール配信サービス